Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2012 pp 447–467Cite as

Antirheumatika und Antiphlogistika

  • Chapter

Zusammenfassung

In der Therapie rheumatischer Erkrankungen einschließlich degenerativer Veränderungen werden vorzugsweise nichtsteroidale Antiphlogistika eingesetzt (Abbildung 16.1).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): „Aus der UAW-Datenbank“: Kardiovaskuläre Nebenwirkungen sind ein Klasseneffekt aller Coxibe: Konsequenzen für ihre künftige Verordnung. Dtsch Ärztebl 101: A 3365.

    Google Scholar 

  • Bannwarth B, Richez C (2011): Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 10: 123-131.

    Article  PubMed  CAS  Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528.

    Article  PubMed  CAS  Google Scholar 

  • Brater DC, Harris C, Redfern JS, Gertz BJ (2001): Renal effects of COX-2 selective inhibitors. Am J Nephrol 21: 1-15.

    Article  PubMed  CAS  Google Scholar 

  • Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.

    Google Scholar 

  • Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D et al (2001): Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53: 343-353.

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthri- tis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771-1781.

    Article  PubMed  CAS  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104-2110.

    Article  PubMed  CAS  Google Scholar 

  • Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 869.

    Article  Google Scholar 

  • Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413-421.

    Article  PubMed  CAS  Google Scholar 

  • Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29: 1581-1582.

    PubMed  Google Scholar 

  • DeAngelis CD, Fontanarosa PB (2008): Impugning the integrity of medical science. The adverse effects of industry influence. JAMA 299: 1833-1835.

    Article  PubMed  CAS  Google Scholar 

  • DeWitt DL (1999): Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55: 625-631.

    PubMed  CAS  Google Scholar 

  • Dreser H (1899): Pharmakologisches über Aspirin (Acetylsalicylsaüre). Pflügers Arch 76: 306-318.

    Article  CAS  Google Scholar 

  • Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet 354: 2106-2111.

    Article  PubMed  CAS  Google Scholar 

  • Eras J, Perazella MA (2001): NSAIDs and the kidney revistied: are selective cyclooxygena- se-2 inhibitors safe? Am J Med Sci 321: 181-190.

    Article  PubMed  CAS  Google Scholar 

  • European Medicines Agency (2005): Public Statement. European Medicines Agency an- nounces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: www.emea.eu.int/htms/hotpress/d6275705.htm

  • European Medicines Agency (2007): Press release. European Medicines Agency recom- mends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdf

  • FDA Alert for Healthcare Professionals (2005): Valdecoxib (marketed as Bextra). Publiziert am 7. April 2005 unter: www.fda.gov/bbs/topics/news/ 2005/NEW01171. html

  • FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: www.fda.gov/bbs/topics/news/2004/new01148.html

  • Food and Drug Administration (2004): FDA Public Health Advisory: Safety of Vioxx. Publiziert am 30. September 2004 unter: www.fda.gov/cder/drug/infopage/vioxx/ PHA_vioxx.htm

  • Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sorensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Kober L, Torp-Pedersen C (2009): Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy indi- viduals: A nationwide cohort study. Clin Pharmacol Ther 85: 190-197.

    Article  PubMed  CAS  Google Scholar 

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppressi- on of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737-16740.

    PubMed  CAS  Google Scholar 

  • Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005): Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475-481.

    PubMed  CAS  Google Scholar 

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer preven- tion with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257-262.

    PubMed  CAS  Google Scholar 

  • Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM (1998): Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irri- tant in the rat stomach. Brit J Pharmacol 123: 927-935.

    Article  CAS  Google Scholar 

  • Hawkey CJ (1999): COX-2 inhibitors. Lancet 353: 307-314.

    Article  PubMed  CAS  Google Scholar 

  • Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al (2000): Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 43: 370-377.

    Article  PubMed  CAS  Google Scholar 

  • Jüni P, Rutjes AWS, Dieppe PA (2002): Are selective COX 2 inhibitors superior to traditio- nal non steroidal anti-inflammatory drugs? Brit Med J 324: 1287-1288.

    Article  PubMed  Google Scholar 

  • Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (2005): Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157-164.

    PubMed  CAS  Google Scholar 

  • Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776-783.

    Article  PubMed  CAS  Google Scholar 

  • Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD Logan RF, Murphy M, Vessey MP, Colin-Jones DG (1994): Risks of bleeding peptic ulcer associated with in- dividual non-steroidal anti-inflammatory drugs. Lancet 323: 1075-1052.

    Article  Google Scholar 

  • Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al (1999): Adverse up- per gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282: 1929-1933.

    Article  PubMed  CAS  Google Scholar 

  • Lin J, Zhang W, Jones A, Doherty M (2004): Efficacy of topical non-steroidal antiinflamm- atory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. Brit med J 329: 324-326.

    Article  PubMed  CAS  Google Scholar 

  • Manger B, Michels H, Nüsslein HG, Schneider M, Sieper J und die Kommission Pharmakotherapie der DGRh (2007): Neufassung der Empfehlungen der Kommission Pharmakotherapie der DGRh. Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 66: 72-75.

    Article  PubMed  CAS  Google Scholar 

  • Meyer R (2005): Pfizer nimmt Bextra vom Markt. Dtsch Ärztebl 102: A 1023.

    Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693-11697.

    Article  PubMed  CAS  Google Scholar 

  • Mukherjee D, Nissen SE, Topol EJ (2001): Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.

    Article  PubMed  CAS  Google Scholar 

  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005): Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091.

    Article  PubMed  CAS  Google Scholar 

  • Patel AM, Moreland LW (2010): Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 4: 263-278.

    PubMed  Google Scholar 

  • Peskar BM, Maricic N, Gretzera B, Schuligoi B, Schmassmann A (2001): Role of cyclooxy- genase-2 in gastric mucosal defense. Life Sci 69: 2993-3003.

    Article  PubMed  CAS  Google Scholar 

  • Piroxicam Rote-Hand-Brief (2007): Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. Internet: www.akdae.de/20/40/Archiv/2007/40-20071011.pdf

  • Prescribe international 2010: Rheumatoid arthritis: choice of antirheumatic treatment. Prescribe international 19: 30-34.

    Google Scholar 

  • Psaty BM, Kronmal RA (2008): Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. A case study based on documents from rofecoxib litigation. JAMA 299: 1813-1817.

    Article  PubMed  CAS  Google Scholar 

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gas- trointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759-766.

    Article  PubMed  CAS  Google Scholar 

  • Ross JS, Hill KP, Egilman DS, Krumholz HM (2008): Guest authorship and ghostwri- ting in publications related to rofecoxib. A case study of industry documents from rofecoxib litigation. JAMA 299: 1800-1812.

    Article  PubMed  CAS  Google Scholar 

  • Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Petersen C, Gislason GH (2011): Duration of treatment with nonsteroidal anti-inflammatory drugs and impact of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123: 2226-2235.

    Article  PubMed  CAS  Google Scholar 

  • Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group (2004): Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665-674.

    Article  PubMed  CAS  Google Scholar 

  • Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K (2010a): Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 1. Dtsch Ärztebl 107: 279-285.

    Google Scholar 

  • Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD (2010b): Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 2. Dtsch Ärztebl 107: 295-301.

    Google Scholar 

  • Shi S, Klotz U (2008): Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233-252.

    Article  PubMed  CAS  Google Scholar 

  • Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000): Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284: 1247-1255.

    Article  PubMed  CAS  Google Scholar 

  • Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA (2010): A genome-wide study identifies HLA alleles associated with lumiracoxib- related liver injury. Nat Genet 42: 711-714.

    Article  PubMed  CAS  Google Scholar 

  • Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, Filippini G, Skoetz N, Francis D, Lopez LC, Guyatt GH, Schmitt J, La Mantia L,Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R (2011): Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev CD 008 794; 1-58.

    Google Scholar 

  • Smolen JS, Kalden JR, Scott DJ, Rozman B, Kvien TK, Larsen A et al. for the European Leflunomide Study Group (1999): Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, rando- mised, multicentre trial. Lancet 353: 259-266.

    Article  PubMed  CAS  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.

    Article  PubMed  CAS  Google Scholar 

  • Solomon DH, Schneeweiss S, Glynn RJ, Kiota Y, Levin R, Mogun H, Avorn J (2004): Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial in- farction in older adults. Circulation 109: 2068-2073.

    Article  PubMed  CAS  Google Scholar 

  • Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011): Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Brit Med J 342: c 7086 1-11.

    Google Scholar 

  • Vane JR (1971): Inhibition of Prostaglandin synthesis as a mechanism of action for aspi- rin-like drugs. Nat New Biol 231: 232-235.

    PubMed  CAS  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Medizin Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Böger, R., Schmidt, G. (2012). Antirheumatika und Antiphlogistika. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-29242-2_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-29241-5

  • Online ISBN: 978-3-642-29242-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation